Relationship between expression of Aurka and clinicopathological characteristics in gastric cancer patients ()
2. MATERIALS AND METHODS
2.1. Patient Characteristics
After inform consent forms were signed, the specimens including gastric cancer and corresponding noncancerous gastric tissues in general surgery of affiliated hospital of North Sichuan Medical College during April to July in 2013 were collected. All cases were diagnosed as gastric adenocarcinoma with pathological biopsy both preoperation and postoperation. They who had taken anti-HP drug or chemotherapy or radiotherapy lately were removed. The clinicopathological characteristics of patients are summarized in Table 1.
Table 1. Patient clinicopathological characteristics.
2.2. Samples
All samples consisted of gastric cancer and corresponding non-cancerous gastric tissues were obtained intraoperation just after they were cut off. Then part were put into −80˚C refrigerator quickly used for total RNA extraction. The left were dipped in formalin and then embedded with paraffins for INH.
2.3. Detection of HP
Patients were arranged to take 14C-urea breath test to detect HP value preoperation. They whose HP values lower than 100 dpm were regarded as negative, and the others positive. Due to cardia complete obstruction or poor compliance, 11 patients did not accept 14C-urea breath test.
2.4. RT-PCR
104 gastric cancer and corresponding non-cancerous gastric tissues were ground into fine powder with mortars and pestles in liquid nitrogen. Then total RNA was extracted with TRizol Reagent (Tiangen, China). Later the quality of total RNA was assessed with ultraviolet spectrophotometer (SHIMADZU, Japan) and agarose gel electrophoresis (agarose from Sigma, America; electrophoresis apparatus from BIO-RAD, America). cDNA was synthesized using reverse transcription kit (BioBRK, China) according to instruction. RT-PCR thermocycler (ABI, America) and kit (Takara, Japan) including Pre Mix, Dye and DNase/RNase free ddH2O were used for cDNA amplification. 1 μl cDNA, 10 μl Pre Mix, 2 μl Dye, forward and reverse primer both 0.6 μl (10 pmol/μl) and 5.8 μl DNase/RNase free ddH2O were consisted in amplification system. Aurka and β-actin primers were synthesized by invitrogen company. The primer sequence, reaction condition and product size are all in Table 2. All samples were tested duplicately. After amplification finished, dissociation curve was analysed to identify the uniqueness of product. 2−∆CT was used as relative expression value.
2.5. INH
Paraffins embeded 104 gastric cancer and corresponding non-cancerous gastric tissues were sectioned to 3 μm in thickness. After the slices were dipped in dimethylbenzene twice each for 10 min, they were put into 100% alcohol, 85% alcohol and 75% alcohol successively, and then washed with running water for deparaffinization. 3% H2O2 covered the whole tissues on slices for 20 min at room temperature and away from light in order to block endogenous peroxidase activity. Heat antigen retrieval was performed in 0.01 M citrate buffer (ph 6.0) at 95˚C for 20 min. Then slices were incubated with Rabbit anti-
Table 2. Primer sequence, reaction condition and product size.
Aurka monoclonal antibody (ABCAM, England) at a dilution of 1:150 (final concentration: 6.67 μg/ml) at 4˚C overnight. At the next morning the slices were incubated with common secondary antibody (ABCAM, England) at room temperature for 15 min. After colorated with diaminobenzidine and counterstained with hematoxylin, the reaction products were visible. All slices were assessed by two professors of pathology who had no knowledge of any clinicopathological characteristics of the patients. Immunohistochemical results were evaluated for intensity and staining frequency of nuclear and cytoplasmic components. The intensity of staining was graded 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The frequency was graded from 0 to 4 according to the percentage of positive cells as follows: 0, ≤3%; 1, ≤4% to 25%; 2, ≤26% to 50%; 3, ≤51% to 75%; 4, ≥75%. The products of multiplication of the intensity and frequency grades were then classified into an index core on a scale of 0 to 3: index score 0 = product of 0 (negative), index score 1 = products of 1 and 2 (weak), index score 2 = products of 3 and 4 (moderate), index score 3 = products of 6 through 12 (strong) [8].
2.6. Statistical Analysis
T-test or One-way analysis of variance were used for PCR data statistics, and Chi-square test was used for INH results. P < 0.05 was considered to have statistical significance.
3. RESULTS
3.1. Expression of Aurka Gene by RT-PCR
3.1.1. Expression of Aurka Gene in Gastric Cancer and Corresponding Non-cancerous Gastric Tissues
The mean ∆CT value of Aurka in gastric cancer and corresponding non-cancerous gastric tissues were 6.63 ± 1.85; 17.20 ± 1.59 (t = −38.58, p < 0.01) Figure 1, The difference was of statistical siginificance. The amplification curve and dissociation curve are in Figure 2.
3.1.2. Relationship between Aurka Gene Expression and HP of Gastric Cancer Patients
The mean ∆CT value of Aurka in gastric cancer tissues of HP positive and negative patients were 5.70 ± 1.86 and 7.88 ± 1.73 respectively. The variation was siginificant (t = −3.74, P < 0.05; Table 3).
3.1.3. Relationship between Aurka Gene Expression and Clinicopathological Characteristics of Gastric Cancer Patient
The CEA data of 3 patients and CA19-9 of 2 patients were lost, so they were removed when made those two statistics analysis. No siginificant relationship was found between Aurka and clinicopathological characteristics, including gender, age, tumor’s location, depth of invasion, differentiation, lymph node metastasis, stage and CEA, CA19-9 level in peripheral blood preoperation (all P > 0.05; Table 4).
3.2. Expression of Aurka Protein by INH
The difference between positive rate of Aurka protein in gastric cancer and corresponding non-cancerous gastric tissues, 94.2% (49/52) and 15.4% (8/52), was significant in statistics (P < 0.01). See Figures 3 and 4.
4. DISCUSSION
The human Aurka gene located in chromosome band 20q13.2, full-length cDNA contains 1212 kb open reading frame encodes a molecular weight of 46 kDa, 403amino acid serine/threonine kinases. Aurka are positioned at the center body From copy to the end of the mitosis [9]. In addition, Aurka also appeared in the microtubule region near the center of the body [10] can regulate centrosome separation, maturation and spindle assembly, play an important role in cell cycle G2/M phase transition and the detection point .In 1998, Human Aurka Gene was first cloned from the colon while it was determined to be oncogene, because overexpression of Aurka can tumor born mice [7]. Aurka also significantly upregulated in a variety of other tumor tissues and various cancer cell lines due to gene amplification and enhanced translation [11,12]. Sen [13] first discovered Aurka overexpression in primary mammary, subsequent study has also found Aurka certain extent overexpressed in the human breast, ovary, pancreas, stomach tumors. Tumor formation is the cumulative result of a series of genetic mutations, there is prevalence phenomenon of genomic instability in a variety of tumor cells [14] just as gastric cancer. The mutation of Cancer-related genes, including oncogenes, tumor suppressor genes and genetic stability (e.g., DNA repair gene) can cause the genome instability [15]. According to the known cytological features of Aurka, we speculate Aurka may be involved in tumor formation through two functions: First, inhibit the cytokinesis split in the process of mitosis which made the instability of genomic [16,17]. Second, inhibit the checkpoint of cell cycle, helping instability cells of the genomic continue to replicate, continue to enter mitosis, leading to cell malignant proliferation.
In esophageal, gastric metaplasia, intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, Pap, esophageal adenocarcinoma, the expression level of Aurka in esophageal mucosa is gradually increasing [18],which showing its expression in esophageal carcinogenesis through the whole process and plays an important role in the incidence and the development process of esophageal cancer, And yet in this regard reported in gastric cancer, if we can find some of its relationship with the pathological features of gastric cancer through research, then the next preoperative endoscopic biopsy of the tumor preliminary assessment will help to guide clinical treatment. However, very few similar studies, whether there has relationship between the expression of Aurka and pathological features of gastric cancer and HP values are related, there is no research in this area yet at home and abroad; Also there is no reports at home and abroad whether there has relationship between their peripheral blood CEA and CA19-9 levels in patients with gastric cancer as well as with gender, age, worthing further study. In this study, RT-PCR and immunohistochemical methods are used to detect the levels of Aurka in gastric cancer and normal tissues from gene and protein, respectively, combined with clinical data and tumor pathological characteristics of patients were compared to clarify the above-described problems.
Our experiment results, both Aurka gene and protein expressing in gastric cancer tissues were significantly higher than in corresponding non-cancerous tissues, con-
Figure 1. The mean ∆CT value of Aurka in gastric cancer and corresponding non-cancerous gastric tissues.
Table 3. The expression of aurka gene in gastric cancer tissues in HP.
Figure 2. The amplification curve and the dissociation curve.
Table 4. The expression of aurka gene in gastric cancer tissues in different clinicopathological characteristics
firmed it is an oncogene [7]. Nevertheless, no relationship was found between Aurka expression in gastric cancer tissues and pathological characteristics including tumor’s location, depth of invasion, differentiation, lymph node metastasis and stage. HP infection is related to gastric canceration [19,20]. It is an important initiating factor of chronic atrophic gastritis, a precancerous disease of gastric cancer, and can induce the sequential event chronic atrophic gastritis developing to gastric mucosa intestinal metaplasia and to gastric cancer [21,22] speculated throught research result that HP infection could up regulate expression of Aurka, and participate in the early stage of gastric canceration. Our results, Aurka expressing notably higher in gastric cancer tissues of HP positive patients than HP negative ones, accorded with their conclusion. In addition, there was no relation between Aurka expression and gender, age, CEA and CA19-9 level in peripheral blood preoperation. CEA and
Figure 3. The expression of aurka protein in gastric cancer and corresponding non-cancerous gastric tissues
(a)(b)
Figure 4. Aurka Protein Expression in Gastric Cancer Tissues (Positive) (a) and Corresponding Non-cancerous Gastric Tissues (Negative) (b) (both magnification × 200).
CA19-9 level in peripheral blood can be used to assess prognosis of gastric cancer patients [23,24] So it can be speculated that Aurka is unable to act as an indicator of gastric cancer prognosis .there is no unanimous conclusion that the mechanism of Aurka gene in gastric cancer, the development process, pending our further study. There has yet reports on Aurka gene and prognosis in patients with gastric cancer, therefore, to explore Aurka gene and prognosis of gastric cancer patients is worth further study. So follow-up to the patients in this study would be very important to make it clear.
5. CONCLUSION
Both Aurka gene and protein expressed significantly higher in gastric cancer tissues than paracancerous, which suggests that Aurka might play a significant role in the procession of the formation and development of gastric cancer as an oncogene. Its effect might be strengthened by HP infection. The expression level of Aurka gene had nothing to do with clinicopathological parameters including tumor’s location, depth of invasion, differentiation, lymph node metastasis, stage; Also, it had nothing to do with clinicopathological parameters including gender, age and CEA, CA19-9 level in peripheral blood preoperation of gastric cancer patients, which suggests that although there has a closely relationship between Aurka and gastric cancer, it can’t be as a prognostic indicator of relapse and speculate for gastric cancer.